arrow
C

Chantiya Chanswangphuwana

division of hematology
H指数:12
被引数:1,450

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prediction model for survival outcome in patients with acute myeloid leukemia: a multicenter prospective cohort study from Thai Acute Leukemia Working Group

急性髓系白血病患者生存结局的预测模型:泰国急性白血病工作组的多中心前瞻性队列研究

2026-08-300
OA
Real-world survival, cognitive, and quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma

新诊断的原发性中枢神经系统淋巴瘤采用甲氨蝶呤/异环磷酰胺联合全脑放疗的生存、认知及生活质量结局

2025-12-140
OA
Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group

通过流式细胞术优化慢性淋巴细胞白血病的诊断标志物:来自泰国全国淋巴瘤研究组的结果

2025-10-080
OAAI
Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity

基于基线急性移植物抗宿主病严重程度的第7天治疗反应评估表现

2025-09-250
PRE
Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand

阿扎胞苷联合维奈克拉治疗急性髓系白血病的真实世界结局:一项来自泰国的多中心回顾性队列研究

2025-09-090
OA
Real-world data on adult AML with FLT3-ITD mutation from the Thai acute leukemia working group

泰国急性白血病工作组提供的成人FLT3-ITD突变急性髓系白血病的真实世界数据

2025-08-290
OA
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHD

MAGIC复合应答:一种整合临床和生物标志物参数的急性GVHD新型终点指标

2025-08-190
OAAI
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

移植物抗宿主病治疗期间的系列临床和生物标志物监测确定了不同的风险阶层,包括超低风险组

2025-01-010
PRE
Detection of MRD Using IGH Assay By NGS after Second Cycle of Chemotherapy in Adult B-Lymphoblastic Leukemia Predicts Poor Clinical Outcomes: Results from a Multicenter Study

成人B淋巴细胞急性白血病在第二化疗周期后使用NGS通过IGH检测微小残留病预测不良临床结局:一项多中心研究的结果

BLOOD
IF23.1
2024-11-050
PRE
Amphiregulin, ST2, and REG3 α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
2024-06-140
OAAI
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
2024-04-233
OAAI
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
2023-09-1210
OAAI
The utility of biomarkers in acute GVHD prognostication
2023-08-318
OAAI
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
2023-08-1113
OAAI
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
2022-06-2320
OAAI
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease

评估Elafin作为急性移植物抗宿主病的预后生物标志物

2021-12-0113
OAAI